Try our mobile app

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

Published: 2021-08-18 17:30:00 ET
<<<  go to LLY company page

- New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis

- Heart failure accounts for more than one million hospitalizations a year in the U.S.

RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 18, 2021 /PRNewswire/ -- Jardiance® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Jardiance is not for people with type 1 diabetes as it may increase the risk of diabetic ketoacidosis in these patients. It is not for use to improve glycemic control in adults with type 2 diabetes with an eGFR